TNF and Crohn disease: A study by Cross et al. found that patients with Crohn’s disease exposed to vedolizumab had an increased incidence of PE (IRR 3.01, 95% CI 1.11–8.18) and DVT (IRR 2.67, 95% CI 1.32–5.41) compared with those exposed to anti-TNF agents138.